- About Amarin-

Amarin in Numbers

Trusting the development of your solutions to Amarin team increases the chances of obtaining a superior product compared to the reference product.

23+
Markets
16+
Developments
60M
Patches

Explore our portfolio and learn how our products provide greater efficiency, lower costs and a longer shelf life.

Portfolio
- We are Amarin -

Shaping the future of pharma

Amarin is an Argentine company specialized in the development and manufacturing of topical and transdermal pharmaceutical products. Based in Buenos Aires, we combine proprietary technologies with over three decades of experience to deliver innovative formulations and generic solutions. 

Our GMP-certified plant and modern laboratories allow us to manage the complete process: from R&D and pilot GMP batches for clinical studies to full-scale commercial manufacturing. Guided by cGMP and GLP standards, our multidisciplinary team ensures the highest levels of quality and compliance. 

We also provide pre-clinical and BA/BE clinical studies, offering monitoring, statistical analysis, and full clinical program management under GLP and GCP guidelines. 

At Amarin, we are committed to turning pharmaceutical challenges into ready-to-scale transdermal solutions trusted by global partners.

- OUR TEAM -

Upper Management

- our history -

Amarin Legacy

1983

Amarin is an Argentine company established in the City of Buenos Aires

1990

Estradiol TDS licensed and supplied to Wyeth Ayerst in Latam for more than 10 years

1999

TDS Technology Transfer to Indian Company Zydus Cadila

2000

Analgesic patch developed by Amarin

2007

Analgesic patch exports from Argentina to EU began

2010

Helm AG became a shareholder and marketing agent for Amarin

2011

Formulations and manufacturing of analgesic pain patch transferred to EU (LTS & IBSA)

2016

Patches for cronic pain and dementia associated with Parkinson out-licensed to a multinational company in Latam

2017

Built up our own manufacturing plant

2018

Diclofenac sodium 1% gel developed by Amarin and approved by US FDA

2019

Patches for dementia associated with Parkinson: launched in Argentinean market and with successful results on a BE Study performed in Brazil

2019

Mercosur certification achieved, including ANVISA approval

2021

First international exports of our patches for dementia associated with Parkinson.

2023

Successful market launch of patches for cronic pain.

2023

Expansion into Oral Films technology.

2024

Facility upgrade with new HPLC systems.

2025

Start of cronic pain patches exports to global markets.
- Our Testimonials -

What our clients say about us.

Vincent Mancinelli II

Former President, Rhodes Pharmaceuticals, US

I have found the leadership and team to be professional, knowledgeable, committed, flexible and extremely reliable. They are capable of developing complex, quality transdermal delivery systems and I recommend Amarin Technologies as a business partner.

Rainer Hoffman

Former President of LTS Lohmann Therapie-Systeme AG

I have followed developments at Amarin Technologies for nearly 30 years. (…). It has been a pleasure to deal with Amarin’s managers and I trust the company will also do well in the future.

Andrew Gardiner

Former CEO, Libero Pharma Ltd.

 I have worked with Amarin since 2006. Throughout that time they have been completely committed to our projects and have added value (…). Their professionalism, flexibility, initiative and creativity have been pivotal in helping us achieve our goals.

Omar Corazza

Former Global Purchase Manager, Adium

Based on our positive experience throughout the years working together, where we could see the commitment and professionalism of Amarin, we consider this company as a strategic partner for any transdermal project.

John Peck

Former Head of BD and Product Selection for Hikma, US

I have partnered with Amarin for the development of multiple complex transdermal products. They proved over and over again the strong technical skills needed to fully develop and commercialize challenging formulations.

- Our Testimonials -

What client say about us.

Dr. Rosana Kaun

Business Manager
“Lorem Ipsum has been the industrys most standar dummy text ever since of type and scrambled make and more.”

Dr. Rosana Kaun

Business Manager
“Lorem Ipsum has been the industrys most standar dummy text ever since of type and scrambled make and more.”

Dr. Rosana Kaun

Business Manager
“Lorem Ipsum has been the industrys most standar dummy text ever since of type and scrambled make and more.”

Dr. Rosana Kaun

Business Manager
“Lorem Ipsum has been the industrys most standar dummy text ever since of type and scrambled make and more.”
- Latest News -

Latest news & article from laboratory.